Skip to main content
Log in

Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status

The society of surgical oncology resident essay award winner

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The overall prognosis of patients with thick cutaneous melanoma (TCM) is generally thought to be poor. Surgically staging these patients with sentinel lymph node (SLN) biopsy remains controversial. This study was performed to determine whether SLN status improved our ability to predict outcome over other known prognostic factors and to develop a model incorporating independent prognostic factors to estimate the risk of recurrence for an individual patient.

Methods

A prospective database identified patients with TCM (>4.0 mm or Clark level V) and clinically negative nodes who underwent SLN biopsy. Univariate and multivariate analyses were performed.

Results

From 1991 to 2001, 126 patients were identified; 75 (60%) were male. The median age was 60 years. The median tumor thickness was 5.5 mm, and 43% were ulcerated. Thirty percent of patients had a positive SLN. Recurrence was seen in 50 patients (40%). Median follow-up, relapse-free survival, and overall survival were 25, 50, and 68 months, respectively. Factors independently predictive of recurrence were age ≥60 years, depth >5.5 mm, ulceration, and SLN positivity. SLN status was the most significant prognostic factor (P< .001). The relative risk of recurrence for an individual patient ranged from 1 in patients for whom no adverse factors were present to 29.4 when all factors were present.

Conclusions

SLN status was the strongest independent predictor of outcome in patients with TCM. However, patients with TCM are prognostically heterogeneous, and all independently predictive factors should be considered when an individual patient’s risk of recurrence is assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Balch CM. Surgical management of regional lymph nodes in cutaneous melanoma.J Am Acad Dermatol 1980;3:511–24.

    Article  PubMed  CAS  Google Scholar 

  2. Balch CM, Soong SJ, Milton G, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.Ann Surg 1982;196:677–84.

    Article  PubMed  CAS  Google Scholar 

  3. Kim S, Garcia C, Rodriguez J, Coit D. Prognosis of thick cutaneous melanoma.J Am Coll Surg 1999;188:241–7.

    Article  PubMed  CAS  Google Scholar 

  4. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma.Ann Surg Oncol 2000;7:160–5.

    Article  PubMed  CAS  Google Scholar 

  5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J Clin Oncol 2001;19:3622–34.

    PubMed  CAS  Google Scholar 

  6. Beahrs OH, Meyers MH, eds.Manual for Staging of Cancer: American Joint Committee on Cancer. 2nd ed. Philadelphia: Lippincott, 1983.

    Google Scholar 

  7. Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds.Manual for Staging of Cancer: American Joint Committee on Cancer. 3rd ed. Philadelphia: Lippincott, 1988.

    Google Scholar 

  8. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds.Manual for Staging of Cancer: American Joint Committee on Cancer. 4th ed. Philadelphia: Lippincott, 1992.

    Google Scholar 

  9. Fleming ID, Cooper JS, Henson DE, et al., eds.Manual for Staging of Cancer: American Joint Committee on Cancer. 5th ed. Philadelphia: Lippincott-Raven, 1997.

    Google Scholar 

  10. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol 2001;19:3635–48.

    PubMed  CAS  Google Scholar 

  11. Coit DG. How we do it: the Memorial Sloan-Kettering Cancer Center approach. In: Cody HS III, ed.Sentinel Lymph Node Biopsy. London: Martin Dunitz, 2002:135–42.

    Google Scholar 

  12. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity.Arch Surg 1990;125: 322–6.

    PubMed  CAS  Google Scholar 

  13. Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma.Br J Plast Surg 1997;50: 349–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel G. Coit MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrone, C.R., Panageas, K.S., Busam, K. et al. Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status. Annals of Surgical Oncology 9, 637–645 (2002). https://doi.org/10.1007/BF02574479

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02574479

Key Words

Navigation